AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$IBRX

Cohen Cheryl sold $851K of IBRX

Cohen Cheryl sold 81,056 shares of ImmunityBio, Inc. (IBRX) at $10.50 ($0.85M total) on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cohen Cheryl
Published Oct 6, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IBRX
Bearish
high confidence
Mentioned
$IBRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IBRXBearishLow
01

Why it matters

The disclosure provides fresh, primary‑source information about insider activity, which can influence short‑term price dynamics.

02

Market read

Insider sales are closely monitored; this filing may prompt traders to reassess short‑term positioning in IBRX.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the sale.

Relevance 4/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filing discloses a director's open‑market sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$IBRXBearishHigh confidence
Context

Director Cheryl Cohen sold 81,056 shares of ImmunityBio for $851,088 via a 10b5-1 plan, reducing her holdings to 100,309 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell.

Evidence & confidence

Form 4 filings are primary source; a director sale of over $800k is material for a micro‑cap biotech and often triggers short‑term selling.

Market effects

Sector

May raise caution for other small‑cap biotech stocks as insider sales are watched closely.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal; impact confined to ImmunityBio and its immediate peer group.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • company
    ImmunityBio, Inc.

    Biotech firm listed on NASDAQ (IBRX).

  • person
    Cheryl Cohen

    Director of ImmunityBio who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IBRX insider trading history →

Related articles

NOV 4
$IBRXMedAI 8/10

ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio (NASDAQ: IBRX) announced the first European patients treated with ANKTIVA plus BCG for BCG-unresponsive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar support commercialization and distribution across Europe.

finanznachrichten.de2 min
NOV 4
HighAI 8/10

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio has begun treating the first patients in Europe with ANKTIVA® plus BCG for BCG-unresponsive non-muscle invasive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar are supporting commercialization and distribution efforts across Europe.

stocktitan.net2 min
OCT 26
$IBRXMedAI 9/10

Expanded Use for ImmunityBio Drug

ImmunityBio Inc. received FDA approval for expanded use of Anktiva to treat a more common form of bladder cancer, months ahead of schedule. The stock rose 4% on the news but has since fallen. Anktiva was initially approved in April 2024 for a rare form of bladder cancer. The FDA had rejected an earlier expanded use application but approved it in October 2024.

labusinessjournal.com3 min
OCT 22
$IBRXLowAI 8/10

ImmunityBio (IBRX): November ANKTIVA Trial Results Could Support Expanded FDA Filing?

ImmunityBio (IBRX) completed the database lock for its QUILT-2.005 trial, evaluating ANKTIVA plus BCG in BCG-naïve NMIBC patients. An FDA-requested interim analysis showed a statistically significant longer duration of complete response with the combination. Topline results are expected in November 2026, with a supplemental Biologics License Application planned for Q4 2026, according to the company.

rttnews.com1 min
OCT 21
$IBRXMedAI 8/10

IBRX Stock Rises: ImmunityBio Expects November Results For Anktiva Bladder Cancer Trial

ImmunityBio (IBRX) announced the completion of data collection for a 366-patient trial of ANKTIVA plus BCG in non-muscle invasive bladder cancer, with final results expected in November. The company reported a statistically significant interim analysis and plans to submit a supplemental Biologics License Application to the FDA in Q4 2026. IBRX shares rose 2% on the news.

stocktwits.com2 min